nNOS and Neurological, Neuropsychiatric Disorders: A 20-Year Story / 神经科学通报·英文版

In the central nervous system, nitric oxide (NO), a free gas with multitudinous bioactivities, is mainly produced from the oxidation of L-arginine by neuronal nitric oxide synthase (nNOS). In the past 20 years, the studies in our group and other laboratories have suggested a significant involvement of nNOS in a variety of neurological and neuropsychiatric disorders. In particular, the interactions between the PDZ domain of nNOS and its adaptor proteins, including post-synaptic density 95, the carboxy-terminal PDZ ligand of nNOS, and the serotonin transporter, significantly influence the subcellular localization and functions of nNOS in the brain. The nNOS-mediated protein-protein interactions provide new attractive targets and guide the discovery of therapeutic drugs for neurological and neuropsychiatric disorders. Here, we summarize the work on the roles of nNOS and its association with multiple adaptor proteins on neurological and neuropsychiatric disorders.

nNOS and Neurological, Neuropsychiatric Disorders: A 20-Year Story / 神经科学通报·英文版

In the central nervous system, nitric oxide (NO), a free gas with multitudinous bioactivities, is mainly produced from the oxidation of L-arginine by neuronal nitric oxide synthase (nNOS). In the past 20 years, the studies in our group and other laboratories have suggested a significant involvement of nNOS in a variety of neurological and neuropsychiatric disorders. In particular, the interactions between the PDZ domain of nNOS and its adaptor proteins, including post-synaptic density 95, the carboxy-terminal PDZ ligand of nNOS, and the serotonin transporter, significantly influence the subcellular localization and functions of nNOS in the brain. The nNOS-mediated protein-protein interactions provide new attractive targets and guide the discovery of therapeutic drugs for neurological and neuropsychiatric disorders. Here, we summarize the work on the roles of nNOS and its association with multiple adaptor proteins on neurological and neuropsychiatric disorders.

Recent advances in understanding the roles and molecular mechanisms of cannabidiol in neuropsychiatric disorders / 药学学报

italic>Cannabis sativa, one of the ancient medicinal plants, has been used to alleviate pain and seizures. However, cannabinoids are often addictive, which limits their clinical use. Cannabidiol (CBD) as a non-psychoactive component of Cannabis sativa, has much weaker adverse effects than Δ9-tetrahydrocannabinol (THC) and therefore has received widespread attention. CBD has been found to ameliorate a variety of neuropsychiatric diseases, but the precise mechanism(s) of action are still unclear. Due to its low affinity for classical cannabinoid receptors current studies are focusing on other targets outside the endocannabinoid system. In the present review we mainly summarize the effects and molecular mechanisms of CBD in neuropsychiatric disorders, including epilepsy, neuropathic pain, anxiety, and depression.

Recent research progress in the field of translational medicine / 上海交通大学学报（医学版）

Translational medicine is a new research system for rapid translation from basic research achievement to clinical treatment. This article summarized the research progress in the field of translational medicine in the recent months, and carried out an inventory of the frontier from important journals (such as Nature, Science, J Clin Invest, Nat Genet, Cell, Eur Heart J) in order to provide references for scientists and doctors, and promote the translation from basic medicine to clinical diagnosis and treatment.

Recent research progress in the field of translational medicine / 上海交通大学学报（医学版）

Translational medicine is a new research system for rapid translation from basic research achievement to clinical treatment. This article summarized the research progress in the field of translational medicine in the recent months, and carried out an inventory of the frontier from important journals (such as Nature, Science, J Clin Invest, Nat Genet, Cell, Eur Heart J) in order to provide references for scientists and doctors, and promote the translation from basic medicine to clinical diagnosis and treatment.

Research progress of the antidepressants targeting the glutamate receptors / 中国药理学通报

Depression is a worldwide neuropsychiatric disorder. Currently most preclinical and clinical studies of depression focus on monoaminergic system. However, there is growing evidence which suggests that glutamatergic system plays a critical role in the pathophysiology of depression. This review focuses on the de-velopment of new antidepressants that target glutamatergic sys-tem, summarizes the current mechanisms of antidepressants, and also highlights new insights to the pathophysiology of depression.

Analysis of clinical and biochemical spectrum of Wilson Disease patients.

Background and Aims: Wilson disease (WD) is autosomal recessive disorder of copper metabolism. Wilson disease patients usually suffer from hepatic or neuropsychiatric complications. The symptoms appear between ages five to 35 but it can vary from two years to 72 years. Materials and Methods : Study was carried out from June 2008 to November 2010. This study included nine families with eleven cases of WD to determine clinical presentation, diagnostic findings (including laboratory results) and liver histology. It included 11 patients who presented with hepatic manifestations and/or Neuropsychiatric manifestations and/or family history suggesting features of WD. Patients with hepatitis B and C and those with history of taking antipsychotic drugs were excluded from the study. Patient's data was included in a well designed performa. Liver function test, serum ceruloplasmin, serum copper, 24 hour urinary copper, blood complete picture were analyzed. Quantitative data such as age, hemoglobin etc were expressed as mean with ± SD and quantitative variables such as sex, movement disorders, hepatic involvement etc were expressed as frequency and percentage. Results: There were five male and six female patients with evidence of various manifestations here (i) hepatic in which they had only liver dysfunction (ii) hepatic and neurological (iii) neurological. The mean age of presentation was 8.7±3.92 years (range 4-19 years) and 45% were male patients. Decreased serum ceruloplasmin, enhanced 24-h urinary copper excretion and signs of chronic liver damage were confirmed in all patients and Kayser-Fleischer rings (KF rings) in 72% of patients. In severe WD patients, serum prothrombin activity was less than 50%, serum ceruloplasmin were low and serum copper levels were high than those in non-severe WD patients. High degree of suspicion leads to early treatment with good outcome. Conclusions: The WD is rare but important cause of chronic liver disease. Clinical and biochemical analysis in cases of patients with unexplained liver disease with high degree of suspicion can lead to early treatment with good outcome.

Encefalopatía hepática en el 2011 / Hepatic encephalopaty in 2011

Hepatic encephalopathy (HE) is a neuropsychiatric and motor disorder, resulting from hepatic failure. It is one of the main manifestations of chronic liver disease and the cardinal presentation of acute liver failure. Its presence and severity are the main prognostic determinants among these patients. It is frequent in advanced chronic liver disease (30-45 percent) and in patients with TIPS (transjugular intrahepatic portosystemic shunt) (10-50 percent). Its pathogenesis is complex and it has multiple components, including ammonia, inflammatory cytokines, benzodiazepine- and manganese-like components, which alter the function of the neuronal cell. Its management requires identification and treatment of the precipitating factors, and ruling out other causes of mental status alteration. The majority of the therapies are aimed at reducing ammonia load in the intestine, such as non absorbable disaccharides (lactulose), antibiotics (neomycin, metronidazole and currently, rifaximin) and other, whose role has yet to be established. Severe encephalopathy is considered an indicator for liver transplantation. This article will analyze mainly hepatic encephalopathy in cirrhotic patients, its classification, etiopathogeny and current management.

La encefalopatía hepática (EH) es un síndrome neuropsiquiátrico y motor, que resulta de una disfunción hepática. Es una de las manifestaciones principales de la enfermedad hepática crónica y la presentación cardinal en la falla hepática aguda. Su presencia y gravedad son uno de los mayores determinantes pronósticos en estos pacientes. Es frecuente en enfermedad hepática crónica avanzada (30-45 por ciento)y en portadores de shunt postosistémico transyugular intrahepático (TIPS) (10-50 por ciento). Su patogénesis es compleja y tiene múltiples componentes, incluyendo el amonio, citoquinas inflamatorias, compuestos que semejan a benzodiacepinas y manganeso, que causan alteración funcional de la célula neuronal. El manejo requiere identificar y tratar los factores precipitantes, además de excluir otras causas de alteración del estado mental. La mayoría de las terapias están dirigidas a reducir la carga de amonio en el intestino, tales como los disacáridos no absorbibles (lactulosa), antibióticos (neomicina, metronidazol y actualmente rifaximina) y otros cuyo rol está por establecerse. La encefalopatía grave es considerada un indicador para trasplante hepático. En este artículo analizaremos principalmente la encefalopatía hepática en pacientes con cirrosis, su clasificación, etiopatogenia y manejo actual.

Kluver-Bucy Syndrome (review) / 中国康复理论与实践

@#Kluver-Bucy syndrome (KBS) is a rare neuropsychiatric disorder. The characteristics of KBS include visual agnosia, hyperorality, changes in dietary habits, hypermetamorphosis, placidity, hypersexuality, and etc. However, some features like aphasia, amnesia,dementia and seizure are probably exclusive to humans. KBS is usually associated with lesions of the bilateral temporal lobe.